InvestorsHub Logo
Followers 32
Posts 5818
Boards Moderated 0
Alias Born 05/23/2006

Re: None

Wednesday, 01/29/2020 8:54:00 AM

Wednesday, January 29, 2020 8:54:00 AM

Post# of 345964
just a matter of time...

from interviews...

Subcutaneous daratumumab (Darzalex), which takes 5 minutes to administer rather than 4 to 8 hours for IV administration or 90 minutes for rapid infusion, offers a more convenient treatment option for patients. As such, once subcutaneous daratumumab becomes available, it will have a widespread use in the early relapse setting, predicts Martin.

https://www.onclive.com/onclive-tv/dr-martin-on-biomarkerdriven-therapeutics-in-multiple-myeloma

and another doctor waiting on SC delivery...

https://www.survivornet.com/articles/an-exciting-development-in-delivery-of-daratumumab-for-multiple-myeloma/
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News